Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Consulting agrmnt
Inv. presentation
DYNAVAX TECHNOLOGIES CORP (DVAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million • Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year • Conference call today at 4:30 p.m. ET/1:30 p.m. PT"
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 SC 13G Deep Track Capital, LP reports a 5.1% stake in Dynavax Technologies Corporation
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 144 Form 144 - Report of proposed sale of securities:
05/02/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance • 2022 total revenue of $723 million, up 64% from $439 million in 2021 o HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 o CpG 1018® adjuvant vaccine net product revenue of $588 million • 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-50% • Increased strength of financial position with year-end cash and investments of $624 million • Conference call today at 4:30 p.m. ET/1:30 p.m. PT"
02/09/2023 SC 13G VANGUARD GROUP INC reports a 6.5% stake in Dynavax Technologies Corp.
02/09/2023 SC 13G/A STATE STREET CORP reports a 7.8% stake in AMEMDED FILING DYNAVAX TECHNOLOGIES CORP
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 9.9% stake in DYNAVAX TECHNOLOGIES CORPORATION
01/09/2023 8-K Investor presentation
Docs: "Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results • Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 • Preliminary full year CpG 1018® adjuvant Net Product Revenue of approximately $588 million • Maintained strong financial position with year-end cash and investments of approximately $624 million • Phase 1 shingles trial results demonstrate favorable tolerability with similar vaccine response rates in CpG 1018 adjuvanted arms versus comparator vaccine EMERYVILLE, CA – January 9, 2023 –&#x202f",
"B PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL PARTNER 1, 2"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/17/2022 SC 13D/A Bain Capital Life Sciences Fund, L.P. reports a 3.9% stake in Dynavax Technologies Corporation
08/04/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/09/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy